drugset
drugset / Trial / NCT05572255

A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally

NCT05572255 ↗

Phase 1 Completed 24 enrolled SK Life Science, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

This study is a phase 1, randomized, open-label, single center, single-dose, 6-sequence, 3-period, 3-treatment crossover study in healthy adult male and female subjects to assess: the relative bioavailability of a crushed 200 mg, intact (whole) 200 mg and crushed 200 mg tablet via NG tube of cenobamate. All treatments will be administered under fasting conditions.

Timeline

Start
2022-09-27
Primary completion
2023-01-28
Completion
2023-01-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Cenobamate Small molecule 200 mg Oral

Indications

No indication recorded.